Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Axillary radiotherapy and surgery show comparable long term outcomes for...

Prof Emiel Rutgers - Netherlands Cancer Institute Amsterdam, Netherlands

Axillary radiotherapy and surgery show comparable long term outcomes for patients with breast cancer ( Prof Emiel Rutgers - Netherlands Cancer Institute Amsterdam, Netherlands )

Gilteritinib combined with induction and consolidation chemotherapy in newly...

Dr Keith Pratz - Johns Hopkins University, Baltimore, USA

Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...

Dr Tait Shanafelt - Standford University, Stanford, USA

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )

NRAS mutant melanoma: Targeted therapy, are we there yet?

Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany

NRAS mutant melanoma: Targeted therapy, are we there yet? ( Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany )

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with...

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve...

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )

Combination strategies of immunotherapy in breast cancer

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Combination strategies of immunotherapy in breast cancer ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...

Dr David R. Spigel - Tennessee Oncology, Nashville, USA

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )

Cardiac events in stage III NSCLC treated in daily clinical practice

Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

Cardiac events in stage III NSCLC treated in daily clinical practice ( Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands )

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy ( Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands )

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for...

Dr Maria Vittoria Dieci - University of Padua, Padova, Italy

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer ( Dr Maria Vittoria Dieci - University of Padua, Padova, Italy )

More from ecancer